A lubricant container configured to facilitate the delivery of lubricant steadily, over time, within a target cavity such as a vagina or anus is described. The container is composed of a soluble membrane or substrate configured to dissolve at or above body temperature. Subdivisions within the container, preferably established via dividers, are configured to contain differing types of lubricant which are to be released in differing stages after a certain amount of time has elapsed. Differing portions of the container, as well as the dividers, are preferably composed of substrate having differing densities and/or thicknesses to facilitate the time-delay function of the apparatus.

A tampon and delivery system for a pharmaceutical, holistic or medicinal component, includes: (1) a nonabsorbent vaginal implant having a generally cylindrical shape including a leading end and a cylindrical outer surface; (2) an outer delivery sheath applied to at least a portion of the cylindrical outer surface of the tampon, distal from the leading end (and preferably leaving the leading end exposed), where the outer delivery sheath comprises a formulation including (a) a water soluble polymer film carrier and (b) a pharmaceutical, holistic or medicinal component; and (3) an applicator containing the tampon and applied delivery sheath. Methods for preparation of the delivery system and methods of use are also disclosed.

Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.

The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

A tampon and delivery system for a pharmaceutical, holistic or medicinal component, includes: (1) a nonabsorbent vaginal implant having a generally cylindrical shape including a leading end and a cylindrical outer surface; (2) an outer delivery sheath applied to at least a portion of the cylindrical outer surface of the tampon, distal from the leading end (and preferably leaving the leading end exposed), where the outer delivery sheath comprises a formulation including (a) a water soluble polymer film carrier and (b) a pharmaceutical, holistic or medicinal component; and (3) an applicator containing the tampon and applied delivery sheath. Methods for preparation of the delivery system and methods of use are also disclosed.

Today's suppositories are typically packaged individually for digital administration into the anal canal of a patient. A suppository applicator described herein, which works with individually packaged suppositories, can alternatively be shipped in a prepackaged operational arrangement with a suppository to enable the patient to administer the suppository through use of the applicator in a single operation after opening a hygienic wrapper containing the applicator-suppository combination. A method for manufacturing a suppository includes manufacturing the suppository in the presence of and in contact with an element configured to be used to insert the suppository into a body cavity. The method may include using the element to define a shape of the suppository during the manufacturing. The resulting applicator-suppository combination is more hygienic and easier to handle than the separate applicator and suppository and provides more efficiency from time of opening the packaging to time of commencing administration of the suppository

Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.

Described herein are medical devices and medical implements with high lubricity to flesh (or biological fluid) and/or inhibited nucleation on its surface. The device has a surface comprising an impregnating liquid and a plurality of micro-scale and/or nano-scale solid features spaced sufficiently close to stably contain the impregnating liquid therebetween. The impregnating liquid fills spaces between said solid features, the surface stably contains the impregnating liquid between the solid features, and the impregnating liquid is substantially held in place between the plurality of solid features regardless of orientation of the surface.

This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.